BMS Reports Result of Opdivo (nivolumab) + Yervoy (ipilimumab) + CT in P-III CheckMate-9LA Study as 1L Therapy for Lung Cancer

 BMS Reports Result of Opdivo (nivolumab) + Yervoy (ipilimumab) + CT in P-III CheckMate-9LA Study as 1L Therapy for Lung Cancer

BMS’s Triple Regimen Receives European Commission Approval for Relapse and Refractory Multiple Myeloma

Shots:

  • The P-III CheckMate -9LA study involve assessing of Opdivo (360mg q3w) + Yervoy (1mg/kg q6w) combined with CT (two cycles) vs CT as monothx. (up to four cycles followed by optional pemetrexed maintenance therapy if eligible) as a 1L treatment in patients with advanced NSCLC regardless of PD-L1 expression and histology
  • The P-III CheckMate -9LA study resulted in meeting 1EPs of superior overall survival (OS) at a pre-specified interim analysis. 2EPs includes PFS, ORR and efficacy measures according to biomarker
  • Opdivo is a PD-1 immune check inhibitor harnessing the body’s own immune system to restore anti-tumor immune response while the Opdivo and Yervoy dual regimen was the first Immuno-Oncology combination to receive approval for metastatic melanoma and is approved in 50+ countries including the US & EU

Click here to­ read full press release/ article | Ref: BMS | Image: Pharmaceutical Technology

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post